U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C4H4O6.Fe
Molecular Weight 203.916
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROUS TARTRATE

SMILES

[Fe++].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O

InChI

InChIKey=OHZCFWMJMWFNFP-ZVGUSBNCSA-L
InChI=1S/C4H6O6.Fe/c5-1(3(7)8)2(6)4(9)10;/h1-2,5-6H,(H,7,8)(H,9,10);/q;+2/p-2/t1-,2-;/m1./s1

HIDE SMILES / InChI
Molecular Formula Fe
Molecular Weight 55.845
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C4H4O6
Molecular Weight 148.071
Charge -2
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/672678 | https://www.ncbi.nlm.nih.gov/pubmed/27138526 | https://www.ncbi.nlm.nih.gov/pubmed/20685224 | https://www.ncbi.nlm.nih.gov/pubmed/26911730

Iron(II) oxide or ferrous oxide is the inorganic compound with the formula FeO. One of several iron oxides, it is a black-colored powder that is sometimes confused with rust, which consists of hydrated iron(III) oxide (ferric oxide). Iron(II) oxide also refers to a family of related non-stoichiometric compounds, which are typically iron deficient with compositions ranging from Fe0.84O to Fe0.95O. Iron(II) oxide makes up approximately 9% of the Earth's mantle. Within the mantle, it may be electrically conductive, which is a possible explanation for perturbations in Earth's rotation not accounted for by accepted models of the mantle's properties. Iron(II) oxide is used as a pigment. It is FDA-approved for use in cosmetics and it is used in some tattoo inks. It can also be used as a phosphate remover from home aquaria.

Originator

Approval Year

1921
1447
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Not Provided
503
Unknown

Approved Use

Unknown
Palliative
Not Provided
503
Unknown

Approved Use

Unknown
Primary
Approved
8360
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
Curative
Approved
8360
RADIOGARDASE

Approved Use

Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination.

Launch Date

1.06496642E12
PubMed

PubMed

TitleDatePubMed
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS.
1932 Jul 1
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.
1932 Nov 11
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A.
1932 Sep 30
[Ferrous lactate as an oral iron preparation for therapeutic use].
1954 Nov 27
Clinical appraisal of drugs with special reference to a new chelate hematinic.
1957 Jul 11
[FERROUS ASPARTATE IN THERAPY].
1964 Jan 1
[Historical notes on the therapy of depression].
1986 Nov 22
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe.
1997 Oct
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.
2007
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study.
2009 Nov 15
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.
2010 Dec
Tolerability of different oral iron supplements: a systematic review.
2013 Apr
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes.
2015 Jun 22
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example.
2017 Jul 5
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes.
2017 Mar 13
Patents

Patents

CN105565963
37
US20020127665
37
US2009028810
37
US20150202224
37
US2877253
37
US3091626
37
US5534268
37
US6407138
37
US8080520
37
US8802114
37

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Thu Jul 06 00:11:35 UTC 2023
Edited
by admin
on Thu Jul 06 00:11:35 UTC 2023
Record UNII
ZRW631PTZD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FERROUS TARTRATE
MART.   WHO-DD  
Common Name English
FERROUS TARTRATE [MART.]
Common Name English
FERRUM TARTARICUM
HPUS  
Common Name English
Ferrous tartrate [WHO-DD]
Common Name English
IRON(II) TARTRATE
Systematic Name English
TARTARIC ACID, IRON(2+) SALT (1:1)
Common Name English
FERRUM TARTARICUM [HPUS]
Common Name English
IRON TARTRATE (FE(C4H4O6))
Common Name English
BUTANEDIOIC ACID, 2,3-DIHYDROXY- (2R,3R)-, IRON(2+) SALT (1:1)
Common Name English
Classification Tree Code System Code
WHO-ATC B03AA08
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
WHO-VATC QB03AA08
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
Code System Code Type Description
PUBCHEM
6451676
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
FDA UNII
ZRW631PTZD
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
DRUG BANK
DB13639
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
EPA CompTox
DTXSID301019697
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
SMS_ID
100000078494
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
ChEMBL
CHEMBL3707386
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
CAS
2944-65-2
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
DRUG CENTRAL
4545
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
ECHA (EC/EINECS)
220-950-1
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
EVMPD
SUB13879MIG
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
WIKIPEDIA
Ferrous tartrate
Created by admin on Thu Jul 06 00:11:35 UTC 2023 , Edited by admin on Thu Jul 06 00:11:35 UTC 2023
PRIMARY
Related Record Type Details
Structure of TARTARIC ACID
PARENT -> SALT/SOLVATE
Structure of FERROUS CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of FERROUS CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966